Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Not applicable Interventional Results available

Clinical Evaluation of the PROGENSA(Registered Trademark) Prostate Cancer Gene 3 (PCA3) Assay in Men With a Previous Negative Biopsy Result

ClinicalTrials.gov ID: NCT01024959

Public ClinicalTrials.gov record NCT01024959. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Clinical Evaluation of the PROGENSA(R) PCA3 Assay in Men With a Previous Negative Biopsy Result

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this multi-center clinical study is to determine the association of the PCA3 Score with prostate biopsy outcome and validate the assay's performance characteristics in men with previous negative prostate biopsies. An elevated PCA3 Score is thought to be associated with an increased likelihood of positive biopsy. The results of this study are intended to be used for regulatory filings for use as an in vitro diagnostic test.

Study identification

NCT ID
NCT01024959
Recruitment status
Completed
Study type
Interventional
Phase
Not applicable
Lead sponsor
Gen-Probe, Incorporated
Industry
Enrollment
507 participants

Conditions and interventions

Interventions

Other

Eligibility (public fields only)

Age range
40 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2009
Primary completion
Mar 31, 2010
Completion
Mar 31, 2010
Last update posted
Nov 11, 2012

2009 – 2010

United States locations

U.S. sites
13
U.S. states
8
U.S. cities
13
Facility City State ZIP Site status
HealthCare Partners Medical Group Los Angeles California 90015
San Diego Clinical Trials San Diego California 92120
South Florida Medical Research Aventura Florida 33180
Specialists in Urology Naples Florida 34102
Florida Urology Specialists Sarasota Florida 34237
Metropolitan Urology, PSC Jeffersonville Indiana 47130
Regional Urology Specialists, LLC Shreveport Louisiana 71106
AccuMed Research Associates Garden City New York 11530
TriState Urologic Services PSC Inc. dba The Urology Group Cincinnati Ohio 45212
Columbus Urology Research, LLC Columbus Ohio 43220
MD Anderson Cancer Center Houston Texas 77030
Urology San Antonio Research San Antonio Texas 78229
Virginia Urology Richmond Virginia 23235

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01024959, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 11, 2012 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01024959 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →